Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder.

Autor:	Nemani K; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.; Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA., De Picker L; Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.; University Psychiatric Centre Duffel, VZW Emmaus, Duffel, Belgium., Dickerson F; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA., Leboyer M; Inserm U955, Translational Psychiatry Laboratory, Université Paris-Est-Créteil, Department of Psychiatry and Addictology of Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Hôpital Albert Chenevier-Henri Mondor, Fondation FondaMental, Créteil, France., Santacatterina M; Department of Population Health, New York University, New York, NY, USA., Ando F; Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA., Capichioni G; Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA., Smith TE; New York State Office of Mental Health, New York, NY, USA., Kammer J; New York State Office of Mental Health, New York, NY, USA., El Abdellati K; Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.; University Psychiatric Centre Duffel, VZW Emmaus, Duffel, Belgium., Morrens M; Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.; University Psychiatric Centre Duffel, VZW Emmaus, Duffel, Belgium., Coppens V; Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.; University Psychiatric Centre Duffel, VZW Emmaus, Duffel, Belgium., Katsafanas E; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA., Origoni A; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA., Khan S; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA., Rowe K; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA., Ziemann RS; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA., Tamouza R; Inserm U955, Translational Psychiatry Laboratory, Université Paris-Est-Créteil, Department of Psychiatry and Addictology of Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Hôpital Albert Chenevier-Henri Mondor, Fondation FondaMental, Créteil, France., Yolken RH; The Stanley Laboratory of Developmental Neurovirology, Johns Hopkins University, Baltimore, MD, USA., Goff DC; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.; Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	Brain, behavior, & immunity - health [Brain Behav Immun Health] 2024 Jun 03; Vol. 38, pp. 100802. Date of Electronic Publication: 2024 Jun 03 (Print Publication: 2024).
DOI:	10.1016/j.bbih.2024.100802
Abstrakt:	Importance: Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population. Objective: To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder. Design: This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine. Setting: A multi-center study including psychiatric healthcare settings in the United States and Europe. Participants: 205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021. Main Outcomes and Measures: Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination. Results: A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (-0.15; 95% CI, -0.27 to -0.03, P  = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (-0.23; 95% CI -0.39 to -0.06, P  = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18- 0.19, P  = 0.96). Conclusions and Relevance: In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu